Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Erasca to Present at Upcoming Conferences in February GlobeNewswire - Thu Feb 5, 7:00AM CST

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? Barchart - Mon Feb 2, 11:45AM CST

Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash,...

ERAS : 12.54 (+1.21%)
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Fri Jan 23, 3:01PM CST

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Erasca Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire - Wed Jan 21, 7:54PM CST

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Erasca Announces Proposed Public Offering of $150 Million of Common Stock GlobeNewswire - Tue Jan 20, 3:01PM CST

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones GlobeNewswire - Mon Jan 12, 7:00AM CST

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015...

ERAS : 12.54 (+1.21%)
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Jan 6, 7:00AM CST

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Erasca to Present at the 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 12.54 (+1.21%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B FinancialNewsMedia - Wed Nov 19, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9640 (-3.60%)
IMRX : 5.00 (-4.76%)
ALXO : 2.45 (-5.77%)
ERAS : 12.54 (+1.21%)
PRLD : 2.78 (+22.47%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B GlobeNewswire - Wed Nov 19, 2025

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9640 (-3.60%)
IMRX : 5.00 (-4.76%)
ALXO : 2.45 (-5.77%)
ERAS : 12.54 (+1.21%)
PRLD : 2.78 (+22.47%)

Barchart Exclusives

NVDA Earnings, Tariffs and Other Key Things to Watch this Week Barchart - Sun Feb 22, 12:00PM CST
Markets enter a critical week dominated by Wednesday's Nvidia earnings and escalating geopolitical tensions as rising U.S.-Iran hostilities push oil prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot